成功治疗 1 例移植后 IgA 肾病患者使用布地奈德靶向释放制剂。
Successful treatment of a patient with posttransplant IgA nephropathy with targeted release formulation of budesonide.
机构信息
Department of Nephrology, Institute of Nephro-urology, Bengaluru, Karnataka, India.
Department of Nephropathology, Manipal Hospitals, Bengaluru, Karnataka, India.
出版信息
Saudi J Kidney Dis Transpl. 2020 Mar-Apr;31(2):521-523. doi: 10.4103/1319-2442.284029.
Recurrence of glomerulonephritis is the third-leading cause of allograft loss. Graft loss due to IgA nephropathy occurs in 10% at 10-year follow-up. The NEFIGAN trial demonstrated that Target Release Formulation (TRF) of budesonide is a specific treatment for IgA nephropathy targeting intestinal mucosal immunity upstream of disease manifestation with favorable safety profile. We are reporting a case of successful treatment of a patient with posttransplant IgA nephropathy with TRF of budesonide.
肾小球肾炎的复发是导致移植物丢失的第三大原因。在 10 年随访中，由于 IgA 肾病导致的移植物丢失发生率为 10%。NEFIGAN 试验表明，布地奈德靶向释放制剂（TRF）是一种针对 IgA 肾病的特异性治疗药物，可针对疾病表现之前的肠道黏膜免疫，具有良好的安全性。我们报告了 1 例使用布地奈德 TRF 成功治疗移植后 IgA 肾病的病例。
Zotero 插件